

1 **Title**

2 **A multicentre point prevalence survey of patterns and quality of antibiotic prescribing in**
3 **Indonesian hospitals**

4
5 **Authors**

6 Ralalicia Limato^{1,2}, Erni J. Nelwan^{3,4,5,6}, Manzilina Mudia¹, Justin de Brabander¹, Helio Guterres^{3,4},
7 Enty Enty^{7,8}, Ifael Y. Mauleti⁹, Maria Mayasari¹⁰, Iman Firmansyah¹¹, May Hizrani⁶, Raph L.
8 Hamers^{1,2,4}

9
10 **Affiliations and addresses**

- 11 1. Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia (Jl. Diponegoro No.69, Jakarta
12 Pusat, DKI Jakarta, Indonesia 10430)
- 13 2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, university of
14 Oxford, Oxford, UK (Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK)
- 15 3. Department of Internal Medicine, Division of Infectious Diseases, Cipto Mangunkusumo
16 National General Hospital, Jakarta, Indonesia (Jl. Pangeran Diponegoro No.71, Jakarta Pusat,
17 DKI Jakarta, Indonesia 10430)
- 18 4. Faculty of Medicine, University of Indonesia, Jakarta, Indonesia (Jl. Salemba Raya No. 6,
19 Jakarta Pusat, DKI Jakarta, Indonesia 10430)
- 20 5. Infectious Disease and Immunology Research Cluster, Indonesian Medical Education and
21 Research Institute, Jakarta, Indonesia (Jl. Salemba Raya No.6, Jakarta Pusat, DKI Jakarta,
22 Indonesia 10430)
- 23 6. Metropolitan Medical Centre Hospital, Jakarta, Indonesia (Jl. H. R. Rasuna Said No.1, Jakarta
24 Selatan, DKI Jakarta, Indonesia 12940)
- 25 7. Royal Taruma Hospital, Jakarta, Indonesia (Jl. Daan Mogot No.34, Jakarta Barat, DKI Jakarta,
26 Indonesia 11470)
- 27 8. Faculty of Medicine and Health Sciences, Atma Jaya Catholic University, Jakarta, Indonesia
28 (Jl. Pluit Selatan Raya No.19, Jakarta Utara, DKI Jakarta, Indonesia 14440)
- 29 9. Fatmawati General Hospital, Jakarta, Indonesia (Jl. RS. Fatmawati Raya No.4, Cilandak Barat,
30 Jakarta Selatan, DKI Jakarta, Indonesia 12430)
- 31 10. St. Carolus Hospital, Jakarta, Indonesia (Jl. Salemba Raya No. 41, Jakarta Pusat, DKI Jakarta,
32 Indonesia 10440)
- 33 11. Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia (Jl. Sunter Permai
34 Raya, Jakarta Utara, DKI Jakarta, Indonesia 14340)

35
36 **Short running title:** antibiotic use in Indonesian hospitals

37 **Inserts:** 4 tables; 3 figures

38 **Data supplement:** 10 tables

39 **Corresponding author**

40 Raph L. Hamers MD PhD

41 Address: EOCRU, Jl. Diponegoro No.69, Jakarta Pusat, DKI Jakarta, Indonesia 10430

42 Email : raph.hamers@ndm.ox.ac.uk

43 Phone : +62 21 31900971

44 Fax : -

45 **Synopsis**

46

47 **Background**

48 Antibiotic misuse and overuse are a major driver of antimicrobial resistance, but systematic data in
49 Indonesia are scarce.

50 **Objectives**

51 To evaluate patterns and quality indicators of antibiotic prescribing in six acute-care hospitals in
52 Jakarta, Indonesia.

53 **Methods**

54 We conducted a hospital-wide point prevalence survey (PPS) between March and August 2019,
55 using Global-PPS and WHO-PPS protocols. The analysis focused on antibacterials for systemic
56 use (antibiotics).

57 **Results**

58 Of 1602 inpatients, 993 (62.0%) received ≥ 1 antimicrobials. Of 1666 antimicrobial prescriptions,
59 1273 (76.4%) were antibiotics. Most common reasons for prescribing were pneumonia (27.7%),
60 skin and soft tissue infections (8.3%), gastrointestinal prophylaxis (7.9%), and gastrointestinal
61 infections (5.4%). The most common indication was community-acquired infection (42.6%),
62 followed by surgical prophylaxis (22.6%), hospital-acquired infection (18.5%), medical prophylaxis
63 (9.6%), unknown (4.6%) and other indications (2.1%). The most prescribed antibiotic classes were
64 third-generation cephalosporins (44.3%), fluoroquinolones (13.5%), carbapenems (7.4%),
65 penicillins with B-lactamase inhibitor (6.8%) and aminoglycosides (6.0%). According to the WHO
66 AWaRe classification, Watch antibiotics accounted for 67.4%, followed by 28.0% Access, 2.4%
67 Reserve, and 2.2% Unclassified. Reason for prescribing, stop/review date and planned duration
68 were poorly documented. Hospital antibiotic guidelines were not available for 28.1% of
69 prescriptions, and guideline compliance was 52.2% (478/915). Parenteral administration was high
70 (85.1%). Targeted (non-empirical) prescriptions comprised 8.1% (44/542) for community-acquired
71 infections and 26.8% (63/235) for hospital-acquired infections.

72 **Conclusions**

73 Our data indicate a high rate of parenteral, empiric use of broad-spectrum antibiotics in Indonesian
74 hospitals, coupled with poor documentation and guideline adherence. The findings suggest
75 important areas for antimicrobial stewardship interventions.

76

77 **Key words**

78 Antimicrobial resistance; antibiotic use; point prevalence survey; antibiotic stewardship; quality
79 indicators; WHO AWaRe; Indonesia

80 Introduction

81

82 Drug-resistant infections have been estimated to account for 700,000 deaths per year globally,
83 cumulating to 10 million by 2050, higher than cancer (8.2 million) or diabetes (1.5 million)
84 combined.¹ The overuse and misuse of antimicrobial agents has been well-recognised as one of
85 the key drivers of emerging antimicrobial resistance (AMR),^{2,3} with antimicrobial consumption
86 projected to rise further globally.⁴ In response to the emerging public health crisis of AMR, the
87 World Health Organisation (WHO) has launched a global action plan, including strategies for
88 surveillance and mitigation of antimicrobial overuse.⁵

89

90 Indonesia, a populous (271 million) and diverse middle-income country, is potentially an AMR
91 hotspot, due to high infectious disease burdens, liberal antibiotic practices, and fragile health
92 systems.^{6,7} The Indonesian government is increasingly supporting antimicrobial stewardship
93 (AMS), through the national action plan on AMR launched in 2014^{8,9}, and as part of hospital
94 accreditation.¹⁰ However, inappropriate or unnecessary antibiotic prescribing is believed to be
95 widespread, although systematic data are lacking to adequately inform AMS policies.

96

97 In global datasets reporting point prevalence surveys (PPS) of antibiotic use in hospitals¹¹⁻¹², low
98 and middle-income countries (LMIC) remain underrepresented to date.^{13,14} The recently introduced
99 WHO AWaRe (Access, Watch, Reserve) antibiotic classification framework, based on accessibility
100 versus AMR potential, is a useful metric to provide an indication of the appropriateness of
101 antibiotic consumption.^{15,16}

102

103 We here report the results of a hospital-wide PPS that evaluated patterns and quality indicators of
104 antibiotic use in six acute-care, general hospitals in Jakarta, the capital city of Indonesia, for
105 community and hospital acquired infections and medical and surgical prophylaxis, by hospital,
106 ward type, indication and diagnosis.

107 **Patients and Methods**

108

109 **Study design and population**

110 We conducted a hospital-wide PPS of antimicrobial use in a purposive sample of six hospitals
111 across Jakarta, between March and August 2019. We followed Global PPS (2018)¹⁷ and WHO
112 (2019)¹¹ protocols. Briefly, PPS is a “snap-shot” survey to collate medical record data on
113 antimicrobial prescriptions in hospitalized patients. Eligible patients were all hospitalised patients
114 who received ≥ 1 active antimicrobial by 8 a.m. on the survey day or surgical prophylaxis ≤ 24 hours
115 prior to the survey. We excluded emergency and day-care wards, outpatient clinics, inpatients who
116 were discharged before or admitted after 8 a.m.

117

118 The study was approved by the Research Ethics Committee of the Faculty of Medicine of the
119 University of Indonesia (1364/UN2.F1/ETIK/2018) and the Oxford Tropical Research Ethics
120 Committee (559-18). The requirement for individual patient consent was waived. Permission was
121 obtained from the hospital management or research/medical committee in each participating
122 hospital.

123

124 **Data collection**

125 Data collection was conducted by 1 or 2 medical doctors from the study team, joined by 1 to 4
126 hospital staff, who received a one-day training and a data collection form (DCF) completion
127 guideline. Each ward was completely surveyed within one day (to minimise the effect of patient
128 movements) and all wards of a single hospital were surveyed within 4 weeks. If crucial patient data
129 was missing, the responsible nurse or clinician was asked for clarifications. A senior team member
130 (RL, RLH) was available to discuss any data queries and take a final decision. We developed a
131 paper DCF comprising ward, patient and treatment sections, modified from Global-PPS¹⁷ and
132 WHO-PPS.¹¹ De-identified data were checked and entered into a study database.

133 We included systemic antimicrobials coded on the basis of the WHO Anatomical Therapeutic
134 Chemical (ATC) classification system as follows: antibacterials (J01), antimycotics (J02),
135 antifungals (D01BA), antimycobacterials (J04), antivirals (J05), nitroimidazole derivatives (P01AB),
136 intestinal anti-infectives (A07A), and antimalarials (P01B). We recorded the diagnosis/reason for
137 the prescribed antimicrobial (what the clinician aimed at treating or preventing), according to a
138 diagnostic code list¹⁷. Antimicrobial indications were classified as: 1) community-acquired infection
139 (CAI) if symptoms were present on admission or started < 48 hours after admission; 2) hospital-
140 acquired infection (HAI) if symptoms started ≥ 48 hours after admission; 3) medical prophylaxis; 4)
141 surgical prophylaxis, categorised as single-dose, one-day, or longer than one day; 5) other; 6)
142 unknown. We recorded the following five quality indicators of prescribing: 1) documentation of
143 diagnosis/reason for antimicrobial use, stop/review date, and treatment duration; 2) hospital
144 antibiotic guideline availability and compliance with regards to drug choice (if not available, this

145 item was recorded as “not assessable”); 3) parenteral administration; 4) culture sample taken in
146 therapeutic use; 5) targeted (antibiotic prescribed in response to microbiology results) or empirical
147 treatment.

148

149 **Statistical analysis**

150 We used descriptive statistics to summarise the data, expressed as counts or percentages, by
151 hospital, ward type, indication and diagnosis. The analysis focused on antibacterials for systemic
152 use (ATC code J01) (aka “antibiotics”). Antibiotics were reported by drug names, chemical class
153 (according to the 4th level WHO ATC classification) and AWaRe groups. We used RStudio
154 Version 1.3.1093 for all analyses.

155

156

157 **Results**

158

159 **Hospital characteristics**

160 Hospitals were tertiary (2) or secondary-level (4), government or private (3 each), including one
161 specializing in infectious diseases (**Table 1**). All hospitals had an antibiotic stewardship team, five
162 hospitals had local antibiotic guidelines, and four hospitals were included in the national health
163 insurance scheme. All 238 inpatient wards across the six hospitals were surveyed, including 87
164 medical, 31 surgical, 95 mixed medical-surgical wards and 25 intensive care units, of which 123
165 adult, 51 paediatric-neonatal and 64 mixed adult-paediatric-neonatal. On the survey day, a total of
166 2358 active hospital beds (median 230, range 134-853 per hospital) accounted for 1602 (67.9%)
167 admitted patients (median 149, range 51-625 per hospital), of whom 993 (62.0%) received ≥ 1
168 antimicrobials (median 91, range 33-368 per hospital). The proportion of patients receiving one or
169 more antimicrobials ranged from 53.5% to 78.8% across hospitals (**Table 1 and S1**).

170

171 **Characteristics of patients receiving one or more antimicrobials**

172 **Table 2** summarizes patient characteristics. Of 993 patients, 497 (50.1%) were women and 782
173 (78.8%) were adults, and the median age was 43 years (IQR 22-58.5; range 1 day to 99 years).
174 One or more comorbidities were documented in 48.9% (486) of patients. 368 (37.1%) had
175 undergone surgery and 299 (30.1%) had been hospitalised in the last 90 days, and 145 (14.6%)
176 had been transferred from another hospital.

177

178 The 993 patients receiving one or more antimicrobials accounted for a total of 1666 active
179 antimicrobial prescriptions (median 1 per patient, range 1-12), with 60.6% (602) receiving one
180 antimicrobial agent, 25.6% (254) two, and 13.8% (137) three or more. Antimicrobial use was
181 highest in ICU (86.8%, 132/152), followed by surgical wards (66.0%, 184/293), mixed medical-
182 surgical wards (65.0%, 401/622) and medical wards (51.4%, 310/569) (**Table S1**). Concomitant

183 use of ≥ 2 antimicrobials was more frequent in ICU (59.1%, 58/98) than non-ICU (37.2%, 333/895)
184 (**Table 2**).

185

186 **Antimicrobial agents prescribed**

187 Of all 1666 antimicrobial prescriptions, 76.4% (1273) were antibacterials, followed by 11.4% (197)
188 antimycobacterials, 4.3% (72) antivirals, 3.7% (62) antimycotics, 2.6% (43) intestinal antiinfectives,
189 0.8% (13) antimalarials, and 0.4% (6) nitroimidazole derivatives. The 1273 prescribed antibiotics
190 (J01) included 46 different agents. The five most prescribed antibiotics were ceftriaxone (26.8%,
191 341), levofloxacin (10.7%, 137), metronidazole (7.1%, 91), meropenem (6.4%, 82) and cefotaxime
192 (5.6%, 71) –accounting for 56.5% (720) of prescriptions (**Table S2**). The five most prescribed
193 antibiotic classes were third-generation cephalosporins (44.3%, 565), fluoroquinolones (13.5%,
194 172), carbapenems (7.4%, 94), penicillins with B-lactamase inhibitor (6.8%, 86) and
195 aminoglycosides (6.0%, 76) (**Figure 1**) –accounting for 78.0% (993) of prescriptions.

196

197 **Reasons for antibiotic prescribing**

198 The full list of diagnosis/reasons for all 1666 antimicrobial prescriptions is included in the data
199 supplement (**Table S3**). Among all 1273 antibiotic prescriptions (J01), the most common
200 diagnosis/reasons were pneumonia (27.7%, 353), skin and soft tissue infections (8.3%, 106),
201 gastrointestinal prophylaxis (7.9%, 101), and gastrointestinal infections (5.4%, 69) –accounting for
202 49.4% (629) of all prescriptions (**Table 3** and **S4**). Ceftriaxone and levofloxacin were mainly used
203 to treat pneumonia and gastrointestinal infections. Metronidazole was mainly used for skin and soft
204 tissue infections and intra-abdominal infections, and for gastrointestinal prophylaxis. Meropenem
205 was mainly used for pneumonia and sepsis. Cefotaxime was mainly used for pneumonia and for
206 gastrointestinal prophylaxis.

207

208 **Indications for antibiotic prescribing**

209 Among all 1273 antibiotic prescriptions (J01), the most common indication was CAI (42.6%, 542),
210 followed by surgical prophylaxis (22.6%, 288), HAI (18.5%, 235), medical prophylaxis (9.6%, 122),
211 unknown (4.6%, 59), and other (2.1%, 27) (**Table S5**)

212

213 Among CAI (542), the top-5 diagnosis/reasons were pneumonia (42.6%, 231), skin and soft tissue
214 infection (14.2%, 77), gastrointestinal infection (12.2%, 66), sepsis (5.5%, 30), and intra-abdominal
215 infection (5.4%, 29) (**Table S4**). The five most common antibiotics for CAI were ceftriaxone
216 (32.8%, 178), levofloxacin (13.5%, 73), metronidazole (8.1%, 44), meropenem (7.7%, 42), and
217 ampicillin sulbactam (5.4%, 29) –accounting for 67.5% (366) of prescriptions (**Table S6**).

218

219 The most common HAI was hospital-acquired pneumonia (including other HAI) (70.2%, 165),
220 followed by intervention-related infections (including catheter-related blood stream infection,

221 ventilator-associated pneumonia, catheter-related urinary tract infection) (19%, 35), post-operative
222 surgical site infection (13.6%, 32), infection present on admission from another hospital (0.85%, 2)
223 or long-term care facility (0.4%, 1); no *C. difficile*-associated diarrhoea (HAI3) was documented
224 (**Table S7**). The six most common antibiotics for HAI were levofloxacin (18.7%, 44), meropenem
225 (13.6%, 32), ceftriaxone (9.8%, 23), amikacin (6.4%, 15), metronidazole and ceftazidime (6%, 14
226 each) –accounting for 60.4% (142) of prescriptions (**Table S6**).

227

228 Among medical prophylaxis (122), the top-5 diagnosis/reasons were neonatal (20.5%, 25), general
229 (19.7%, 24), gastrointestinal (17.2%, 21), respiratory (15.6%, 19), and unknown (8.2%, 10) (**Table**
230 **S4**). The five most common antibiotics for medical prophylaxis were ceftriaxone (28.7%, 35),
231 cotrimoxazole (17.2%, 21), gentamicin (10.7%, 13), cefotaxime (8.2%, 10), ampicillin (7.4%, 9) –
232 accounting for 72.1% (88) of prescriptions (**Table S6**).

233

234 Among surgical prophylaxis (288), the top-5 diagnosis/reasons were gastrointestinal (27.8%, 80),
235 obstetrics/gynaecology (20.1%, 58), bone and joint (17%, 49), urinary tract (12.8%, 37), central
236 nervous system and ear-nose-throat (7.3%, 21 each). The most common antibiotics for surgical
237 prophylaxis were ceftriaxone (26.4%, 76), cefixime (11.5%, 33), cefoperazone (11.1%, 32),
238 metronidazole (9.7%, 28), cefazolin (6.2%, 18) –accounting for 64.9% (187) of prescriptions.
239 Notably, duration of surgical prophylaxis was longer than one day for 76% (219) of prescriptions,
240 whereas 15.0% (43) was single-dose and 9.0% (26) was for one day.

241

242 **Antibiotic use based on AWaRe groups**

243 **Figure 2** summarizes AWaRe groups. Of all 1273 antibiotic prescriptions (J01), 67.4% (858) were
244 Watch antibiotics, followed by 28.0% (356) Access, 2.4% (31) Reserve, and 2.2% (28)
245 Unclassified. This pattern was similar across indications and ward types. Of note, Watch
246 antibiotics were commonly prescribed for the most frequent diagnosis, i.e. pneumonia (34.4%,
247 295), gastrointestinal infection (6.6%, 57), and skin and soft tissue infection (5.8%, 50). Watch
248 antibiotics (858) comprised 45.1% (387) of CAI, 20.9% (179) of surgical prophylaxis, 19.5% (167)
249 of HAI, and 7.2% (62) of medical prophylaxis. The five most used Watch antibiotics were
250 ceftriaxone (39.7%, 341), levofloxacin (15.8%, 136), meropenem (9.6%, 82), cefotaxime (8.3%,
251 71), and cefoperazone (6%, 52) (**Table S7**).

252

253 Access antibiotics (356) comprised 37.6% (134) of CAI, 27% (96) of surgical prophylaxis, 15.4%
254 (55) of medical prophylaxis, and 13.8% (49) of HAI. The five most used Access antibiotics were
255 metronidazole (25.3%, 90), ampicillin-sulbactam (12.4%, 44), gentamicin (11.8%, 42), amikacin
256 (9%, 32) and amoxicillin-clavulanic acid (8.7%, 31) (**Table S7, Figure 3**).

257

258 Reserve antibiotics were uncommon (31), and included fosfomycin (15, 48.4%), tigecycline (13,
259 41.9%), colistin (1, 3.2%), and linezolid (1, 3.2%).

260

261 **Quality indicators of antibiotic use (J01)**

262 **Documentation of antibiotic plan** Reason for prescribing was documented for 63.5% (808/1273)
263 of all prescriptions, with substantial variation between hospitals, indications and ward types (**Table**
264 **4 and S9**). Documentation of diagnosis/reason was better for therapeutic use (546/777, 70.3%)
265 than prophylactic use (230/410, 56.0%), and in ICU (75.6%, 118/156) than non-ICU (61.8%,
266 690/1117). Stop/review date (15.2%, 194/1273) and planned treatment duration (9.8%, 125/1273)
267 was poorly documented overall, across indications and ward types (**Table 4 and S9**).

268

269 **Hospital guideline availability and compliance** Local antibiotic guidelines were not available for
270 28.1% (358/1273) of antibiotic prescriptions; and, of note, for 76.2% (93/122) of prescriptions for
271 medical prophylaxis. Guideline compliance was 52.2% (478/915) overall, 44.8% (223/498) for
272 empirical CAI treatment, 45.9% (79/172) for empirical HAI treatment, 28.5% (82/288) for surgical
273 prophylaxis and 18.9% (23/122) for medical prophylaxis (**Table 4**). Guideline compliance was
274 similar across ward types (**Table S9**).

275

276 **Parenteral use** 85.1% (1084/1273) of prescriptions were parenterally administered, including
277 88.5% (208/235) for HAI, 89.5% (486/542) for CAI, 75.4% (92/122) for medical prophylaxis and
278 82.3% (237/288) for surgical prophylaxis (**Table 4**). Parenteral use was higher in ICU (97.4%,
279 152/156) than non-ICU (83.4%, 932/1117) (**Table S9**).

280

281 **Culture samples taken** Among 619 patients with ≥ 1 antibiotic for therapeutic use, 48.8% (302)
282 had one or more samples taken for bacterial culture (total 831 samples, median 2, range 1-25 per
283 patient). Among the top-5 diagnosis/reasons for prescribing, one or more culture sample were
284 taken in 44.8% (154/353) of pneumonias, 51.9% (55/106) of skin and soft tissue infections, 66.7%
285 (38/57) of intra-abdominal infections, 52.2% (24/46) of sepsis, and 75.9% (22/29) of upper UTI.
286 Blood cultures were taken in 44.4% (88/353) of pneumonias, 45.6% (26/57) of intra-abdominal
287 infections, 58.6% (17/29) of upper UTI, and 95.8% (23/24) of sepsis. Sputum cultures were taken
288 in 26.9% (95/353) of pneumonias. Urine cultures were taken in 72.4% (21/29) of upper UTI (**Table**
289 **S10**).

290

291 **Targeted antibiotic treatment** Treatment was targeted in 8.1% (44/542) of CAI and 26.8%
292 (63/235) of HAI (**Table 4**); 13.0% (46/353) of pneumonias, 15.8% (9/57) of intra-abdominal
293 infections, 44.8% (13/29) of upper UTI, and 13% (6/46) of sepsis. Targeted treatment was more
294 common in ICU (19.9%, 31/156) than in non-ICU (6.8%, 76/1117) (**Table S9**).

295 Discussion

296

297 This was the first contemporary hospital-wide survey in Indonesia that systematically evaluated
298 patterns and quality of antibiotic prescribing, using the recommended PPS methodology.^{11,17} We
299 demonstrated the feasibility of PPS in this low-resource setting, and generated useful data to
300 guide local AMS programmes. Our survey found a high proportion (62%) of antimicrobial use
301 among hospitalized patients, ranging from 53.5% to 78.8% across hospitals in Jakarta, with the
302 highest use in ICU (86.8%) as expected. Antibiotic use was substantially higher than reported in
303 global PPS datasets, which were dominated by data from high-income countries in Europe, North
304 America and Asia^{13,14} and which highlighted that antimicrobial use was significantly higher in non-
305 European hospitals compared with European hospitals.¹⁴

306

307 Consistent with other surveys in Asia^{18,19} and globally¹³, the predominant reason for antibiotic
308 prescription in Jakarta hospitals were lower respiratory tract infections. In our survey, the mostly
309 used antibiotic classes were third-generation cephalosporines (mainly ceftriaxone),
310 fluoroquinolones (mainly levofloxacin), and carbapenems (mainly meropenem), all predominantly
311 used for pneumonia, among several other diagnosis. Ceftriaxone was the most used antibiotic
312 across all major indications (i.e. CAI, HAI, surgical and medical prophylaxis). These findings are
313 consistent with the widespread use of broad-spectrum antibiotics, predominantly third-generation
314 cephalosporins and fluoroquinolones, in Indonesia²⁰, other Asian countries^{18,19,21-23} and
315 globally^{13,14}, which may suggest that at least a proportion of these prescriptions are unnecessary
316 or inappropriate. Moreover, the empirical use of meropenem for CAI and HAI represented nearly
317 10% of all antibiotics for therapeutic use. This could partially be explained by high rates of AMR,
318 particularly in common Gram-negative organisms, in Indonesian hospitals.²⁴ However, targeted
319 prescribing for CAI (8%) and HAI (27%) was low in comparison to a global study (12-27% and 20-
320 44%, respectively)¹³, suggesting underutilization of microbiological diagnostics as well as overuse
321 of broad-spectrum antibiotics.

322

323 Antibiotic prescriptions for HAI (18.5% of total), predominantly for pneumonia but also intervention-
324 related and post-operative surgical site infections, were comparable to recent surveys in India
325 (19%)¹⁹ and Thailand (34%)¹⁸, but considerably higher than in reports from high-income settings,
326 e.g. ECDC survey (6%)²⁵ and the GLOBAL-PPS survey (8.4%).¹³ These data confirm the
327 significantly higher burden of HAI in LMIC compared to high-income countries.

328

329 A high proportion of antibiotic prescriptions were for surgical (23%) and medical prophylaxis
330 (10%), for a range of indications. Prophylactic prescribing was unusually high for gastrointestinal
331 infections. Prolonged (>1 day) surgical prophylaxis was very common (76%) in our survey, as has

332 also been observed in other countries in Asia (Pakistan 97%²¹, India 77%¹⁹, Thailand 90%¹⁸) as
333 well as in Europe^{13,25}. Prolonged antibiotic prophylaxis for more than 24h for most surgical
334 indications does not prevent development of postoperative infections, compared with <24h, but
335 increases the risk of AMR and side-effects.²⁶ Further research is warranted to explain the reasons
336 for these patterns.

337

338 We investigated five basic quality indicators, which could be used to set benchmarks for quality
339 improvement of antibiotic use²⁷ and AMS programmes.²⁸ Documentation of the reason of
340 prescribing (64%) was lower than reported across studies in Europe, Asia, Africa, and America
341 (70-85%).^{13,29} Stop or review date was poorly documented (15%) across indications and ward
342 types. Post-prescription review of a prescribed antimicrobial within 48-72h of the initial order,
343 ensures appropriate choice and route of administration, optimal de-escalation (IV-oral switch)
344 practices, and prevents unnecessarily long antibiotic courses. The high (85%) proportion of
345 parenteral route of administration, coupled with high rates of empirical therapy and suboptimal use
346 of microbiological cultures, suggests lack of de-escalation protocols in the participating hospitals.
347 Pro-active IV to oral switching policies can reduce catheter-related complications, health-care
348 costs, and duration of hospital stays, and is recognized as a key metric for AMS processes³⁰.

349

350 Hospital guidelines were not available for 28% of antibiotic prescriptions, including for 76% of
351 prescriptions for medical prophylaxis. A systematic review and meta-analysis showed that
352 guideline-adherent empirical therapy was associated with a relative risk reduction for mortality of
353 35%³⁰. The reason for poor guideline compliance is uncertain and probably multifactorial, including
354 local resistance patterns, ineffective guideline dissemination, and clinical uncertainty with fear of
355 treatment failure. Our findings should trigger further detailed investigations at hospital and country
356 level.

357

358 The WHO AWaRe framework offers an attractive metric for LMIC in the absence of validated
359 quality indicators for antibiotic appropriateness^{15,31,32}, and includes a >60% national target of total
360 antibiotic consumption in the Access category by 2023³³. However, a recent assessment of
361 antibiotic consumption data from 76 countries in 2000-2015 found that the global per-capita
362 consumption of Watch antibiotics increased by 90.9%, compared with an increase of 26.2% in
363 Access antibiotics, with disproportionate increases in Watch antibiotic consumption in LMIC (165%
364 compared with 27.9% in high-income countries)¹⁶. Although Indonesia national-level data have not
365 been included in the AWaRE reports to date³³, our survey found hospital consumption of Access
366 antibiotics at 28% to be far below the 60% target, mostly driven by ceftriaxone and levofloxacin
367 use for CAI and HAI. Although these findings could partially be explained by the national health
368 insurance scheme which determines available antibiotics based on the national formulary³⁴, they
369 also highlight significant challenges for AMS.

370

371 The limitations of this study are inherent to the cross-sectional “snap-shot” design. As we used a
372 convenient hospital sample, data are not representative for all hospitals in Jakarta or Indonesia,
373 urging caution in extrapolating the observed patterns. Antibiotic use patterns can be influenced by
374 many factors, e.g. patient case mix, prevalence of different types of infections, AMR patterns,
375 institutional factors, among others.

376

377 In conclusion, we observed high levels of parenteral, empiric use of broad-spectrum antibiotics in
378 Indonesian hospitals, and inadequate performance on key quality indicators of prescribing. Despite
379 important progress in AMS, supported by national policies^{9,10} and guidelines³⁵, the study findings
380 highlighted the need to strengthen AMS to increase use of narrower-spectrum antibiotics through
381 culture-guided targeted treatment and hospital guideline compliance. Further research is needed
382 to understand the complex drivers of antibiotic prescribing, and to develop context-specific and
383 feasible quality improvement strategies to strengthen existing AMS programmes.

384 **Acknowledgements**

385 We thank the management, research/medical committees and clinical staff of the participating
386 hospitals for their support, and Reinout van Crevel and Rogier van Doorn for useful feedback on
387 the manuscript.

388

389 **EXPLAIN study group**

390 Ralalicia Limato, Erni J. Nelwan, Manzilina Mudia, Helio Guterres, Enty Enty, Ifael Y. Mauleti,
391 Maria Mayasari, Iman Firmansyah, May Hizrani, Raph L. Hamers, Anis Karuniawati, Prof Taralan
392 Tambunan, Prof Amin Soebandrio, Prof Henri Verbrugh, Decy Subekti, Iqbal Elyazar, Mutia
393 Rahardjani, Fitria Wulandari, Prof Reinout van Crevel, Rogier van Doorn, Vu Thi Lan Huong, Nga
394 Do Ti Thuy, Sonia Lewycka, Prof Alex Broom.

395

396 **Funding**

397 This work was funded by the Wellcome Trust, UK (106680/Z/14/Z)

398

399 **Transparency declarations**

400 Conflicts of interest: The authors declare no competing interests.

401 Author contributions: EJM and RLH conceived the idea for the study and are the principal
402 investigators. RLH obtained the funding. RL, EJM and RLH designed the study protocol. MM, HG,
403 EE, IYM, MM, IF, and MH collected and verified the data, overseen by RL. RL and MM curated the
404 database, did the analysis and had full access to all study data, supervised by EJM and RLH. RL,
405 MM and RLH drafted the paper. All authors critically revised the manuscript and all authors gave
406 approval for the final version to be published.

407 **References**

- 408 1. O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. *AMR*
409 *Rev Pap* 2014.
- 410 2. Van Boeckel TP, Gandra S, Ashok A, *et al.* Global antibiotic consumption 2000 to 2010: An
411 analysis of national pharmaceutical sales data. *Lancet Infect Dis* 2014; **14**: 742–50. Available at:
412 [http://dx.doi.org/10.1016/S1473-3099\(14\)70780-7](http://dx.doi.org/10.1016/S1473-3099(14)70780-7).
- 413 3. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and
414 association with resistance: a cross-national database study. *Lancet* 2005; **365**: 579–87.
- 415 4. Klein EY, Van Boeckel TP, Martinez EM, *et al.* Global increase and geographic convergence in
416 antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci U S A* 2018; **115**: E3463–70.
- 417 5. World Health Organization (WHO). *Global Action Plan on Antimicrobial Resistance*. 2015.
- 418 6. Zellweger M, Carrique-mas J, Limmathurotsakul D, Day NPJ, Thwaites GE. A current
419 perspective on antimicrobial resistance in Southeast Asia. *J Antimicrob Chemother* 2017; **72**:
420 2963–72. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890732/pdf/dkx260.pdf>.
- 421 7. Coker RJ, Hunter BM, Rudge JW, Liverani M, Hanvoravongchai P. Emerging infectious
422 diseases in southeast Asia: Regional challenges to control. *Lancet* 2011; **377**: 599–609. Available
423 at: [http://dx.doi.org/10.1016/S0140-6736\(10\)62004-1](http://dx.doi.org/10.1016/S0140-6736(10)62004-1).
- 424 8. Parathon H, Kuntaman K, Widiastoety TH, *et al.* Progress towards antimicrobial resistance
425 containment and control in Indonesia. *BMJ* 2017; **358**: 31–5.
- 426 9. Ministry of Health Republic of Indonesia. Minister of Health Republic of Indonesia Policy No. 8
427 Year 2015. 2015.
- 428 10. Hospital Accreditation Committee. Standard Hospital Accreditation 1st Edition. *Komisi*
429 *Akreditasi Rumah Sakit* 2017: 1–421. Available at: [http://akreditasi.kars.or.id/downloads/RS-](http://akreditasi.kars.or.id/downloads/RS-Template.xls)
430 [Template.xls](http://akreditasi.kars.or.id/downloads/RS-Template.xls).
- 431 11. World Health Organization (WHO). *WHO Methodology for Point Prevalence Survey on*
432 *Antibiotic Use in Hospitals Version 1.1*. 2018. Available at:
433 <https://apps.who.int/iris/bitstream/handle/10665/280063/WHO-EMP-IAU-2018.01-eng.pdf?ua=1>.
- 434 12. Versporten A, Bielicki J, Drapier N, *et al.* The worldwide antibiotic resistance and prescribing in
435 european children (ARPEC) point prevalence survey: Developing hospital-quality indicators of
436 antibiotic prescribing for children. *J Antimicrob Chemother* 2016; **71**: 1106–17.
- 437 13. Versporten A, Zarb P, Caniaux I, *et al.* Antimicrobial consumption and resistance in adult
438 hospital inpatients in 53 countries: results of an internet-based global point prevalence survey.
439 *Lancet Glob Heal* 2018; **6**: e619–29. Available at: [http://dx.doi.org/10.1016/%0AS2214-](http://dx.doi.org/10.1016/%0AS2214-109X(18)30186-4)
440 [109X\(18\)30186-4](http://dx.doi.org/10.1016/%0AS2214-109X(18)30186-4).
- 441 14. Saleem Z, Hassali MA, Godman B, *et al.* Point prevalence surveys of antimicrobial use: a
442 systematic review and the implications. *Expert Rev Anti Infect Ther* 2020; **0**: 1. Available at:
443 <https://doi.org/10.1080/14787210.2020.1767593>.
- 444 15. World Health Organization (WHO). WHO releases the 2019 AWaRe Classification Antibiotics.

- 445 2019. Available at:
446 [https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/e](https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/)
447 [n/](https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/).
- 448 16. Klein EY, Milkowska-Shibata M, Tseng KK, *et al.* Assessment of WHO antibiotic consumption
449 and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. *Lancet*
450 *Infect Dis* 2020; **3099**. Available at: [http://dx.doi.org/10.1016/S1473-3099\(20\)30332-7](http://dx.doi.org/10.1016/S1473-3099(20)30332-7).
- 451 17. Goossens H. *Global Point Prevalence Survey of Antimicrobial Consumption and Resistance*
452 *(2018 Global-PPS): Protocol*. 2018.
- 453 18. Thamlikitkul V, Rattanaumpawan P, Sirijatuphat R, Wangchinda W. Integrated one-day
454 surveillance of antimicrobial use, antimicrobial consumption, antimicrobial resistance, healthcare-
455 associated infection, and antimicrobial resistance burden among hospitalized patients in Thailand.
456 *J Infect* 2020; **81**: 98–106. Available at: <https://doi.org/10.1016/j.jinf.2020.04.040>.
- 457 19. Singh SK, Sengupta S, Antony R, *et al.* Variations in antibiotic use across India: multi-centre
458 study through Global Point Prevalence survey. *J Hosp Infect* 2019; **103**: 280–3. Available at:
459 <https://doi.org/10.1016/j.jhin.2019.05.014>.
- 460 20. Hadi U, Kuntaman K, Qiptiyah M, Paraton H. Problem of Antibiotic Use and Antimicrobial
461 Resistance in Indonesia: Are We Really Making Progress? *Indones J Trop Infect Dis* 2013; **4**: 5.
- 462 21. Saleem Z, Hassali MA, Versporten A, *et al.* A multicenter point prevalence survey of antibiotic
463 use in Punjab, Pakistan: findings and implications. *Expert Rev Anti Infect Ther* 2019; **17**: 285–93.
464 Available at: <https://doi.org/10.1080/14787210.2019.1581063>.
- 465 22. Xie D shuang, Xiang L li, Li R, Hu Q, Luo Q qin, Xiong W. A multicenter point-prevalence
466 survey of antibiotic use in 13 Chinese hospitals. *J Infect Public Health* 2015; **8**: 55–61. Available
467 at: <http://dx.doi.org/10.1016/j.jiph.2014.07.001>.
- 468 23. Thu TA, Rahman M, Coffin S, Harun-Or-Rashid M, Sakamoto J, Hung NV. Antibiotic use in
469 Vietnamese hospitals: A multicenter point-prevalence study. *Am J Infect Control* 2012; **40**: 840–4.
- 470 24. Dahesihdewi A, Sugjani AK, Parwati I. *Data Surveilans Mikroba Dan Kepekaannya Terhadap*
471 *Antibiotik Berdasarkan Tipe Rumah Sakit Di Indonesia Tahun 2017*. Jakarta, Indonesia; 2018.
- 472 25. European Centre for Disease Prevention and Control. *Point prevalence survey of healthcare-*
473 *associated infections and antimicrobial use in European acute care hospitals*. Stockholm; 2013.
- 474 26. World Health Organization (WHO). *Global guidelines on the prevention of surgical site*
475 *infection*. Geneva, Switzerland; 2018. Available at: [http://www.who.int/gpsc/ssi-prevention-](http://www.who.int/gpsc/ssi-prevention-guidelines/en/#.WB6CWivkT70.mendeley)
476 [guidelines/en/#.WB6CWivkT70.mendeley](http://www.who.int/gpsc/ssi-prevention-guidelines/en/#.WB6CWivkT70.mendeley).
- 477 27. van den Bosch CMA, Hulscher MEJL, Natsch S, Wille J, Prins JM, Geerlings SE. Applicability
478 of generic quality indicators for appropriate antibiotic use in daily hospital practice: a cross-
479 sectional point-prevalence multicenter study. *Clin Microbiol Infect* 2016; **22**: 888.e1-888.e9.
480 Available at: <http://dx.doi.org/10.1016/j.cmi.2016.07.011>.
- 481 28. Malcolm W, Nathwani D, Davey P, *et al.* From intermittent antibiotic point prevalence surveys
482 to quality improvement: Experience in Scottish hospitals. *Antimicrob Resist Infect Control* 2013; **2**:

- 483 1–9.
- 484 29. Zarb P, Amadeo B, Muller A, *et al.* Identification of targets for quality improvement in
485 antimicrobial prescribing: The web-based ESAC point prevalence survey 2009. *J Antimicrob*
486 *Chemother* 2011; **66**: 443–9.
- 487 30. Schuts EC, Hulscher MEJL, Mouton JW, *et al.* Current evidence on hospital antimicrobial
488 stewardship objectives: A systematic review and meta-analysis. *Lancet Infect Dis* 2016; **16**: 847–
489 56. Available at: [http://dx.doi.org/10.1016/S1473-3099\(16\)00065-7](http://dx.doi.org/10.1016/S1473-3099(16)00065-7).
- 490 31. World Health Organization (WHO). Adopt AWaRe: Handle antibiotics with care. 2019.
491 Available at: <https://adoptaware.org/>.
- 492 32. Sharland M, Pulcini C, Harbarth S, *et al.* Classifying antibiotics in the WHO Essential
493 Medicines List for optimal use—be AWaRe. *Lancet Infect Dis* 2018; **18**: 18–20. Available at:
494 [http://dx.doi.org/10.1016/S1473-3099\(17\)30724-7](http://dx.doi.org/10.1016/S1473-3099(17)30724-7).
- 495 33. World Health Organization (WHO). *WHO report on surveillance of antibiotic consumption:
496 2016-2018 early implementation*. Geneva, Switzerland; 2018. Available at:
497 <https://apps.who.int/iris/bitstream/handle/10665/277359/9789241514880-eng.pdf>.
- 498 34. Yuniarti E, Prabandari YS, Kristin E, Suryawati S. Rationing for medicines by health care
499 providers in Indonesia National Health Insurance System at hospital setting: A qualitative study. *J*
500 *Pharm Policy Pract* 2019; **12**: 1–11.
- 501 35. Ministry of Health Republic of Indonesia. Minister of Health Policy on General Guideline of
502 Antibiotic Use. 2011. Available at:
503 [https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0a](https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwjEh8GnxurXAhVMNI8KHVx6DooQFggzMAE&url=http%3A%2F%2Fjdih.pom.go.id%2Fsho)
504 [http%3A%2F%2Fjdih.pom.go.id%2Fsho](http://jdih.pom.go.id/sho)
505 [wpdf.php%3Fu%3DcTc0eStSVTImXC7Av%252BxK5RLEij8it%252Fhu%252FnLT03HCOs%253](http://jdih.pom.go.id/sho)
506 [D&usg=AOvVaw34g7pV](http://jdih.pom.go.id/sho).
- 507

Table 1. Hospital characteristics

	Total	Hospital 1	Hospital 2	Hospital 3	Hospital 4	Hospital 5	Hospital 6
Level of health service	-	Secondary	Tertiary	Secondary	Secondary	Tertiary	Secondary
Sector	-	Private	Public	Private	Public	Public	Private
Teaching hospital	-	Yes	Yes	Yes	No	Yes	No
National health insurance scheme ^a	-	No	Yes	Yes	Yes	Yes	No
Hospital antibiotic guidelines	-	No	Yes	Yes	Yes	Yes	Yes
Inpatient wards ^b	238	19	74	30	14	79	22
Medical wards	87	4	27	15	6	30	5
Surgical wards	31	0	17	2	0	11	1
Mixed medical-surgical wards ^c	95	12	19	10	7	32	15
Intensive care units	25	3	11	3	1	6	1
Adult	123	8	55	13	2	39	6
Paediatric and/or neonatal	51	5	12	6	3	21	4
Mixed adult-neonatal-paediatric ^d	64	6	7	11	9	19	12
Inpatient beds	2358	159	767	300	145	853	134
Admitted patients	1602 (67.9)	100 (62.9)	562 (73.3)	198 (66.0)	66 (45.5)	625 (73.3)	51 (38.1)
Admitted patients on ≥1 antimicrobials	993 (62.0)	75 (75.0)	368 (65.5)	106 (53.5)	52 (78.8)	359 (57.4)	33 (64.7)
Medical ward	310 (31.2)	47 (62.7)	102 (27.7)	45 (42.5)	14 (26.9)	95 (26.5)	7 (21.2)
Surgical ward	184 (18.5)	0 (0.0)	87 (23.6)	24 (22.6)	0 (0.0)	73 (20.3)	0 (0.0)
Mixed medical-surgical ward ^c	401 (40.4)	23 (30.7)	135 (36.7)	37 (34.9)	35 (67.3)	147 (40.9)	24 (72.7)
Intensive care unit	98 (9.9)	5 (6.7)	44 (12.0)	0 (0.0)	3 (5.8)	44 (12.3)	2 (6.1)
Adult ward	727 (73.2)	31 (41.3)	298 (81.0)	92 (86.8)	43 (82.7)	230 (64.0)	33 (100)
Paediatric ward	163 (16.4)	13 (17.4)	58 (15.7)	8 (7.5)	3 (5.7)	81 (22.6)	0 (0.0)
Mixed adult-neonatal-paediatric ward ^d	103 (10.4)	31 (41.3)	12 (3.3)	6 (5.7)	6 (11.6)	48 (13.4)	0 (0.0)

Data shown reflect the hospital situation on the survey day, and are expressed as number (percentage), unless otherwise specified.

^a National health insurance scheme, *Jaminan Kesehatan Nasional (JKN)*.

^b Includes all inpatients wards in the hospital. Some wards have been further subdivided for the purpose of this survey.

^c Wards that can admit both medical and surgical patients.

^d Wards that can admit both adult, paediatric and neonatal patients.

Table 2. Characteristics of patients receiving ≥ 1 antimicrobials

	Total (n=993)	Hospital 1 (n=75)	Hospital 2 (n=368)	Hospital 3 (n=106)	Hospital 4 (n=52)	Hospital 5 (n=359)	Hospital 6 (n=33)
Female	497 (50.1)	41 (54.7)	186 (50.5)	61 (57.5)	22 (42.3)	175 (48.7)	12 (36.4)
Age (median, IQR) ^a	43 (22-58.5)	29 (20-55)	47 (25-60)	52 (33-66)	39.5 (28-59)	37 (8-53)	51 (28.5-65)
<1 month (neonates)	45 (4.5)	2 (2.7)	17 (4.6)	2 (1.9)	1 (1.9)	23 (6.4)	0 (0.0)
1-23 months	63 (6.3)	3 (4.0)	20 (5.4)	2 (1.9)	1 (1.9)	37 (10.3)	0 (0.0)
2-17 years	103 (10.4)	12 (16.0)	24 (6.5)	6 (5.7)	4 (7.7)	57 (15.9)	0 (0.0)
18-29 years	131 (13.2)	21 (28.0)	47 (12.8)	7 (6.6)	8 (15.4)	39 (10.9)	9 (27.3)
30-39 years	112 (11.3)	9 (12.0)	35 (9.5)	24 (22.6)	12 (23.1)	30 (8.4)	2 (6.1)
40-49 years	145 (14.6)	7 (9.3)	55 (14.9)	7 (6.6)	8 (15.4)	63 (17.5)	5 (15.2)
≥ 50 years	394 (39.7)	21 (28.0)	170 (46.2)	58 (54.7)	18 (34.6)	110 (30.6)	17 (51.5)
National health insurance holder ^b	743 (74.8)	0 (0.0)	329 (89.4)	24 (22.6)	50 (96.2)	340 (94.7)	0 (0.0)
Transfer from other hospital	145 (14.6)	2 (2.7)	70 (19.0)	2 (1.9)	10 (19.2)	57 (15.9)	4 (12.1)
Hospitalisation within 90 days ^c	299 (30.1)	12 (16.0)	86 (23.4)	20 (18.9)	20 (38.5)	151 (42.1)	10 (30.3)
Surgery in the past 90 days ^d	368 (37.1)	3 (4.0)	162 (44.0)	41 (38.7)	8 (15.4)	142 (39.6)	12 (36.4)
Catheter use							
Central vascular	132 (13.3)	4 (5.3)	35 (9.5)	12 (11.3)	1 (1.9)	73 (20.3)	7 (21.2)
Peripheral vascular	941 (94.8)	69 (92.0)	357 (97.0)	85 (80.2)	51 (98.1)	347 (96.7)	32 (97.0)
Urinary	363 (36.6)	9 (12.0)	183 (49.7)	35 (33.0)	9 (17.3)	119 (33.1)	8 (24.2)
Intubation	65 (6.5)	3 (4.0)	21 (5.7)	7 (6.6)	1 (1.9)	30 (8.4)	3 (9.1)
Documented comorbidity							
Malnutrition	335 (33.7)	0 (0.0)	165 (44.8)	17 (16.0)	28 (53.8)	121 (33.7)	4 (12.1)
Diabetes mellitus	161 (16.2)	8 (10.7)	68 (18.5)	24 (22.6)	14 (26.9)	39 (10.9)	8 (24.2)
Tuberculosis	120 (12.1)	3 (4.0)	37 (10.1)	7 (6.6)	24 (46.2)	44 (12.3)	5 (15.2)
HIV	44 (4.4)	3 (4.0)	10 (2.7)	2 (1.9)	13 (25.0)	16 (4.5)	0 (0.0)
HIV on antiretroviral treatment	27 (2.7)	3 (4.0)	4 (1.1)	2 (1.9)	8 (15.4)	10 (2.8)	0 (0.0)
Chronic obstructive pulmonary disease	11 (1.1)	0 (0.0)	7 (1.9)	0 (0.0)	3 (5.8)	1 (0.3)	0 (0.0)
McCabe score ^e							
Rapidly fatal	29 (2.9)	3 (4.0)	8 (2.2)	2 (1.9)	0 (0.0)	15 (4.2)	1 (3.0)
Ultimately fatal	217 (21.9)	3 (4.0)	89 (24.2)	32 (30.2)	2 (3.8)	84 (23.4)	7 (21.2)
Non-fatal	746 (75.1)	69 (92.0)	270 (73.4)	72 (67.9)	50 (96.2)	260 (72.4)	25 (75.8)
Unknown	1 (0.1)	0 (0.0)	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Prescribed antimicrobial drugs							
Median (range) per patient	1 (1-12)	1 (1-12)	1 (1-9)	1 (1-7)	1 (1-6)	1 (1-10)	1 (1-4)
1	602 (60.6)	58 (77.3)	204 (55.4)	74 (69.8)	32 (61.5)	209 (58.2)	25 (75.8)
2	254 (25.6)	11 (14.7)	108 (29.3)	22 (20.8)	8 (15.4)	99 (27.6)	6 (18.2)
≥ 3	137 (13.8)	6 (8.0)	56 (15.2)	10 (9.4)	12 (23.1)	51 (14.2)	2 (6.1)

Data shown reflect the hospital situation on the survey day, and are expressed as number (percentage), unless otherwise specified

^a Median (IQR) age was 47 (28-60) years for adults, 7 (2-11) months for children <2 years, and 8 (3-14) days for neonates

^b Jaminan Kesehatan Nasional (JKN); Unknown for 4 (0.4%) participants.

^c Before the current admission, the patient has been hospitalized within 90 days before the survey date.

^d The patient underwent surgery in the past 90 days before the survey date, including surgery prior to and during the current admission

^e McCabe score is a simple subjective method to assess underlying illness severity and classify patients according to a prognosis of rapidly fatal (<1 year), ultimately fatal (1-4 years) and non-fatal (>5 years) (Reilly et al. J Infect Prev 2016;17(3):127-129).

Table 3. Most common diagnosis for systemic antibiotic use

Diagnosis	Total (n=1,273)
Pneumonia or lower respiratory tract infection	353 (27.7)
Skin and soft tissue infection ^a	106 (8.3)
Prophylaxis for gastrointestinal infections ^b	101 (7.9)
Gastrointestinal infection	69 (5.4)
Prophylaxis for bone and joint infection ^c	58 (4.6)
Prophylaxis for obstetrics or gynaecological infection	58 (4.6)
Intra-abdominal infection ^d	57 (4.5)
Unknown reason	47 (3.7)
Sepsis	46 (3.6)
Prophylaxis for urinary tract infection (surgery or recurrent infection)	42 (3.3)
Other diagnosis ^e	35 (2.7)
Ear, nose, throat infection ^f	30 (2.4)
Upper urinary tract infection ^g	29 (2.3)
Central nervous system infection	26 (2.0)
Medical prophylaxis for new-born risk factors	25 (2.0)

The table lists the 15 most common reasons to prescribe at least one antibiotic for systemic use (J01). Data are expressed as numbers (percentage) and ranked by frequency. Patients recorded with more than one diagnosis were counted by number of diagnoses. Diagnosis were coded based on the GLOBAL-PPS 2018 Diagnostic Code List. The full list of diagnosis is shown in Table S6.

^a Including cellulitis, wound including surgical site infections, deep soft tissue not involving bone (e.g. infected pressure or diabetic ulcers, abscess).

^b Including prophylaxis for surgery of the gastrointestinal tract, liver, or biliary tree, and prophylaxis in patients with neutropenia or hepatic failure.

^c Including prophylaxis for surgical site infections, for plastic or orthopaedic surgery (bone or joint).

^d Including hepatobiliary, intra-abdominal abscess, etc.

^e Antibiotic prescribed with documentation for which there is no above diagnosis group.

^f Including mouth, sinuses, larynx.

^g Including catheter related urinary tract infection, pyelonephritis.

Table 4. Quality indicators for antibiotic prescribing, by indication

Quality indicators	Total (n=1,273)	Therapeutic use (n=777)				Prophylactic use (n=410)		Other indication ^a (n=27)	Unknown indication (n=59)
		CAI empirical (n=498)	CAI targeted (n=44)	HAI empirical (n=172)	HAI targeted (n=63)	Medical prophylaxis (n=122)	Surgical prophylaxis (n=288)		
Reason documented	808 (63.5)	321 (64.5)	35 (79.5)	145 (84.3)	45 (71.4)	58 (47.5)	172 (59.7)	21 (77.8)	11 (18.6)
Stop/review date documented	194 (15.2)	69 (13.9)	7 (15.9)	43 (25.0)	18 (28.6)	15 (12.3)	38 (13.2)	2 (7.4)	2 (3.4)
Treatment duration documented	125 (9.8)	35 (7.0)	5 (11.4)	31 (18.0)	12 (19.0)	3 (2.5)	35 (12.2)	0 (0.0)	4 (6.8)
Guideline compliance									
Yes	478 (37.5)	223 (44.8)	17 (38.6)	79 (45.9)	33 (52.4)	23 (18.9)	82 (28.5)	21 (77.8)	0 (0.0)
No	378 (29.7)	136 (27.3)	16 (36.4)	70 (40.7)	20 (31.7)	6 (4.9)	124 (43.1)	6 (22.2)	0 (0.0)
Not assessable ^b	358 (28.1)	139 (27.9)	11 (25.0)	23 (13.4)	10 (15.9)	93 (76.2)	82 (28.5)	0 (0.0)	0 (0.0)
Indication unknown	59 (4.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	59 (100.0)
Route of administration									
Parenteral (IV)	1,084 (85.2)	444 (89.2)	42 (95.5)	150 (87.2)	58 (92.1)	92 (75.4)	237 (82.3)	10 (37.0)	51 (86.4)
Oral	183 (14.38)	52 (10.44)	2 (4.55)	22 (12.79)	5 (7.94)	30 (24.59)	51 (17.71)	13 (48.15)	8 (13.56)
IV-oral switch	48 (26.2)	6 (11.5)	1 (50.0)	9 (40.9)	1 (20.0)	1 (3.3)	28 (54.9)	0 (0.0)	2 (25.0)
Other	6 (0.47)	2 (0.40)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	4 (14.81)	0 (0.00)
Culture sample taken ^c	344 (44.3)	125 (25.1)	44 (100)	112 (65.1)	63 (100)	-	-	-	-

Abbreviations: CAI, community acquired infection; HAI, hospital acquired infection; IV, intravenous

^a Other indication included antibiotics prescribed for neurotoxoplasmosis, pulmonary tuberculosis, and as motility agent.

^b Hospital antibiotic guidelines were not available to assess compliance.

^c Only applicable to therapeutic use.




Figure 1. Systemic antibiotic use by antibiotic class, by indication




Figure 2. Systemic antibiotic use by AWaRe classification

Total antibiotic use (n=1273) 90.6% DU		Therapeutic use		Prophylactic use				Other Indication (n=27) 85.1% DU	Unknown Indication (n=59) 83.2% DU				
		CAI (n=542) 89.7% DU	HAI (n=235) 89.4% DU	Medical prophylaxis (n=122) 92% DU		Surgical prophylaxis (n=288) 91.4% DU							
Ceftriaxone	341 (26.8)	Ceftriaxone	178 (32.8)	Levofloxacin	44 (18.7)	Ceftriaxone	35 (28.7)	Ceftriaxone	76 (26.4)	Clindamycin	10 (37.0)	Ceftriaxone	29 (49.2)
Levofloxacin	136 (10.7)	Levofloxacin	73 (13.5)	Meropenem	32 (13.6)	Cotrimoxazole	21 (17.2)	Cefixime	33 (11.5)	Streptomycin	10 (37.0)	Cefotaxime	7 (11.9)
Metronidazole	90 (7.1)	Metronidazole	44 (8.1)	Ceftriaxone	23 (9.8)	Gentamicin	13 (10.7)	Cefoperazone	32 (11.1)	Levofloxacin	3 (11.1)	Levofloxacin	5 (8.5)
Meropenem	82 (6.4)	Meropenem	42 (7.7)	Amikacin	15 (6.4)	Cefotaxime	10 (8.2)	Metronidazole	28 (9.7)			Metronidazole	2 (3.4)
Cefotaxime	71 (5.6)	Ampicillin β-LI	29 (5.4)	Metronidazole	14 (6.0)	Ampicillin	9 (7.4)	Cefazolin	18 (6.2)			Meropenem	2 (3.4)
Cefoperazone	52 (4.1)	Cefotaxime	27 (5.0)	Ceftazidime	14 (6.0)	Cefoperazone βLI	6 (4.9)	Amoxicillin βLI	16 (5.6)			Gentamicin	2 (3.4)
Cefixime	51 (4.0)	Gentamicin	17 (3.1)	Cefotaxime	12 (5.1)	Cefoperazone	4 (3.3)	Cefotaxime	14 (4.9)			Amoxicillin	2 (3.4)
Ampicillin βLI	44 (3.5)	Cefixime	12 (2.2)	Ciprofloxacin	9 (3.8)	Ampicillin βLI	4 (3.3)	Levofloxacin	8 (2.8)				
Gentamicin	42 (3.3)	Cefoperazone	11 (2.0)	Cefoperazone βLI	6 (2.6)	Amoxicillin	4 (3.3)	Gentamicin	7 (2.4)				
Amikacin	32 (2.5)	Amikacin	10 (1.8)	Azithromycin	6 (2.6)	Levofloxacin	3 (2.5)	Cefoperazone βLI	6 (2.1)				
Amoxicillin βLI	31 (2.4)	Cefoperazone βLI	9 (1.7)	Tigecycline	6 (2.6)	Erythromycin	3 (2.5)	Amikacin	6 (2.1)				
Cefoperazone βLI	28 (2.2)	Ciprofloxacin	9 (1.7)	Cefoperazone	5 (2.1)			Fosfomycin	6 (2.1)				
Cotrimoxazole	28 (2.2)	Azithromycin	9 (1.7)	Ampicillin βLI	5 (2.1)			Ampicillin βLI	5 (1.7)				
Ceftazidime	21 (1.6)	Amoxicillin βLI	8 (1.5)	Amoxicillin βLI	5 (2.1)			Ampicillin	4 (1.4)				
Ciprofloxacin	21 (1.6)	Moxifloxacin	8 (1.5)	Fosfomycin	5 (2.1)			Cefadroxil	4 (1.4)				
Cefazolin	18 (1.5)			Piperacillin βLI	5 (2.1)								
Ampicillin	17 (1.3)			Doripenem	4 (1.7)								
Amoxicillin	16 (1.3)												
Azithromycin	16 (1.3)												
Clindamycin	16 (1.3)												

Data are expressed as numbers (percentage). Antibacterial prescriptions for systemic use (J01) were included.

Abbreviations: DU 90%, the number of drugs which account for 90% of the prescriptions; CAI, community acquired infection; HAI, hospital acquired infection; βLI, and beta lactamase inhibitor

Figure 3. Systemic antibiotic use by indication based on AWaRe classification